Related Experiment Video
Updated: Aug 20, 2025
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
Targeting epigenetics in diabetic cardiomyopathy: Therapeutic potential of flavonoids
Yutong Zhou1, Wendong Suo2, Xinai Zhang1
1Guang'an Men Hospital, China Academy of Chinese Medicine, Beijing 100053, China.
Abstract:
The pathophysiological mechanisms of diabetic cardiomyopathy have been extensively studied, but there is still a lack of effective prevention and treatment methods. The ability of flavonoids to protect the heart from diabetic cardiomyopathy has been extensively described. In recent years, epigenetics has received increasing attention from scholars in exploring the etiology and treatment of diabetes and its complications. DNA methylation, histone modifications and non-coding RNAs play key functions in the development, maintenance and progression of diabetic cardiomyopathy. Hence, prevention or reversal of the epigenetic alterations that have occurred during the development of diabetic cardiomyopathy may alleviate the personal and social burden of the disease. Flavonoids can be used as natural epigenetic modulators in alternative therapies for diabetic cardiomyopathy. In this review, we discuss the epigenetic effects of different flavonoid subtypes in diabetic cardiomyopathy and summarize the evidence from preclinical and clinical studies that already exist. However, limited research is available on the potential beneficial effects of flavonoids on the epigenetics of diabetic cardiomyopathy. In the future, clinical trials in which different flavonoids exert their antidiabetic and cardioprotective effects through various epigenetic mechanisms should be further explored.
Insights
Flavonoids show promise in preventing diabetic cardiomyopathy by modulating epigenetic changes. Further clinical trials are needed to explore their full therapeutic potential in managing this complex condition.
Area of Science:
- Cardiovascular Research
- Endocrinology
- Epigenetics
Background:
- Diabetic cardiomyopathy (DCM) lacks effective treatments despite extensive research into its pathophysiology.
- Flavonoids are known for their cardioprotective effects against DCM.
- Epigenetics, including DNA methylation, histone modifications, and non-coding RNAs, is increasingly recognized in diabetes and its complications.
Purpose of the Study:
- To review the epigenetic effects of various flavonoid subtypes on diabetic cardiomyopathy.
- To summarize existing preclinical and clinical evidence on flavonoids in DCM.
- To highlight the potential of flavonoids as epigenetic modulators for DCM therapy.
Main Methods:
- Literature review of preclinical and clinical studies.
- Analysis of epigenetic mechanisms (DNA methylation, histone modifications, non-coding RNAs) in DCM.
- Focus on the role of different flavonoid classes.
Main Results:
- Epigenetic alterations are crucial in the development and progression of DCM.
- Flavonoids can act as natural epigenetic modulators.
- Evidence suggests flavonoids may offer a novel therapeutic strategy for DCM.
Conclusions:
- Modulating epigenetic changes offers a potential avenue for preventing and treating DCM.
- Flavonoids represent a promising class of compounds for alternative DCM therapies.
- More clinical research is essential to validate the antidiabetic and cardioprotective effects of flavonoids via epigenetic pathways.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:30Cardiomyopathy II: Dilated Cardiomyopathy
01:22Heart Failure Drugs: Diuretics
01:20Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...